

## Xadago

Abu Dhabi · access guide

# How to access Xadago from Abu Dhabi, the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

An the UAEian patient with Parkinson's disease experiencing OFF-episodes on levodopa/carbidopa may receive a prescription for Xadago (safinamide) from their treating neurologist or movement-disorder specialist. Xadago is FDA-approved as adjunctive therapy for Parkinson's OFF-episodes and developed by Zambon (with US rights held through licensing). It is not a controlled substance. In Abu Dhabi, Xadago is not routinely registered for outpatient dispensing, so access is typically coordinated through the named-patient import pathway.

This guide explains the pathway, documentation your physician prepares, typical timing and cost bands, and where Reserve Meds fits in.

## The clinical situation

Xadago is a once-daily oral monoamine oxidase-B (MAO-B) inhibitor with additional glutamate-modulating activity, taken at 50 mg or 100 mg. Eligibility anchors to established Parkinson's disease, optimised levodopa/carbidopa regimen, and persistent OFF-episodes. Your neurologist will characterise OFF-time, confirm optimal levodopa dose, screen for dyskinesia tolerance, and review concomitant medicines to avoid serotonin-syndrome risk from concurrent MAO inhibitor combinations.

## Is Xadago legally importable into the Abu Dhabi?

Yes, through the UAE Ministry of Health and Prevention (MoHAP) named-patient / special-access import framework. The mechanism permits an the UAEian-licensed physician to import a medicine not locally registered when (a) it is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent registered alternative is suitable, (c) the physician accepts clinical responsibility, and (d) chain of custody is documented.

## How the pathway works, step by step

---

1. **Consultation with your treating neurologist.** Parkinson's diagnosis, levodopa regimen optimisation, OFF-episode diary.
2. **Baseline assessment.** Motor fluctuations, dyskinesia tolerance, concomitant-medication review for serotonergic and MAO-interaction risk, hepatic/ophthalmologic baseline per labeling considerations.
3. **MoHAP named-patient application.** The physician or hospital pharmacy files clinical rationale, patient reference, and dosing plan.
4. **US-side sourcing.** Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Xadago from authorised distribution under DSCSA.
5. **Ambient shipment.** Xadago ships under controlled ambient conditions with chain-of-custody documentation.
6. **Arrival and dispensing.** The hospital pharmacy releases the bottle with titration and concomitant-medicine guidance.

## What documentation your physician needs

---

- Clinical rationale letter confirming Parkinson's with OFF-episodes and Xadago as the indicated adjunct
- Verification of the UAEian medical license
- Levodopa/carbidopa regimen documentation
- OFF-episode diary evidence
- Concomitant-medication review
- Planned dosing schedule (typically 50 mg titrated to 100 mg)

Reserve Meds provides a physician documentation kit bundling templates MoHAP reviewers expect for Parkinson's adjunct named-patient imports.

## Costs and timing

---

Xadago's US cash-pay drug-only reference cost sits in an indicative 2026 annual range of roughly USD 8,000-11,000 for continuous daily dosing. International logistics, MoHAP documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake. Indicative range.

Indicative timing for first dispense after cohort intake opens is 7-14 days from the moment a complete MoHAP application is submitted.

*Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.*

## Reserve Meds's role

---

- **Sourcing.** Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
- **Documentation.** Regulatory package for your physician and MoHAP review.
- **Logistics.** Ambient-controlled shipment to your prescribing hospital.
- **Concierge case lead.** A named point of contact coordinating monthly refills.

**What we do not do:** We are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.

## Frequently asked

---

**Is this legal in Abu Dhabi?** Yes, when executed through the MoHAP named-patient framework with appropriate documentation. See our trust and compliance page.

**Is Xadago a controlled substance?** No. Safinamide is not a scheduled controlled substance.

**How does Xadago compare with rasagiline or selegiline?** All three are MAO-B inhibitors; Xadago adds glutamate-modulating activity. Your neurologist selects based on the clinical picture, concomitant medicines, and tolerability.

**What are the key drug interactions?** Concurrent use with other MAO inhibitors, opioid analgesics such as meperidine, and certain serotonergic agents is contraindicated. Your neurologist will review your full medication list at initiation.

**Will insurance cover this?** Cash-pay is the default. Some the UAEian private insurers consider case by case; we supply documentation but do not process claims directly.

### *Reserve Meds's role*

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

---

### Reserve Meds

*reserved for you.*

Composite case examples. This document is for general information only and does not constitute medical advice. Please consult your treating physician.

Reserve Meds is in pre-launch. Published timelines and cost ranges are indicative, not guarantees.

reservemeds.com · hello@reservemeds.com